ABCC8 p.Val118Ile
| Predicted by SNAP2: | A: N (87%), C: N (78%), D: D (71%), E: D (63%), F: N (82%), G: N (53%), H: N (57%), I: N (97%), K: D (66%), L: N (93%), M: N (82%), N: D (59%), P: D (66%), Q: D (59%), R: D (63%), S: N (61%), T: N (93%), W: D (63%), Y: D (59%), |
| Predicted by PROVEAN: | A: N, C: N, D: N, E: N, F: N, G: D, H: N, I: N, K: N, L: N, M: N, N: N, P: D, Q: N, R: N, S: N, T: N, W: N, Y: N, |
[switch to compact view]
Comments [show]
None has been submitted yet.
[hide] A study of seven rule-based algorithms for the int... J Virol Methods. 2008 Jul;151(1):79-86. Epub 2008 May 6. Poonpiriya V, Sungkanuparph S, Leechanachai P, Pasomsub E, Watitpun C, Chunhakan S, Chantratita W
A study of seven rule-based algorithms for the interpretation of HIV-1 genotypic resistance data in Thailand.
J Virol Methods. 2008 Jul;151(1):79-86. Epub 2008 May 6., [PMID:18462814]
Abstract [show]
Since the free therapy program was started by the Thai government, the number of patients infected by HIV-1 with access to antiretroviral drugs has increased. The selection of effective interpretation algorithms for antiretroviral drug resistance has become even more important for clinical management. In this retrospective study, the level of agreement was evaluated in 721 antiretroviral-therapy failing HIV-1 subjects. Regarding genetic diversity, about 89% was recognized as non-B variants (CRF01_AE). The level of complete concordant interpretation score in all seven algorithms was recognized in non-nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs) (67%), but not in nucleoside reverse transcriptase inhibitors (NRTIs) (52%). Over 10% of the major discordance score with TRUGENE was revealed in didanosine (Agence Nationale de Recherches sur le SIDA[ANRS]; Detroit Medical Centre [DMC]), abacavir (ANRS; Centre Hospitalier de Luxembourg [CHL]), and also with delavirdine, indinavir and amprenavir (Grupo de Aconselhamento Virologico [GAV]). A good to excellent agreement range of kappa scores was detected for most antiretroviral drugs. However, poor agreement with the TRUGENE system (k<0.40) was seen in the ANRS system with didanosine, abacavir and lopinavir; GAV system in indinavir and amprenavir; and DMC system in ritonavir. These might be an option for resource limited countries when selecting the use of a low cost or free algorithm interpretation, which has excellent agreement as the U.S. Food and Drug Administration (FDA)-approved TRUGENE commercial system.
Comments [show]
None has been submitted yet.
No. Sentence Comment
72 Among 668 (96.7%) other patients infected with non-B HIV-1 variants, the subtype/CRF distribution in decreasing order Table 1 Prevalence of pol gene mutation associated with antiretroviral drug resistance for NRTIs, NNRTIs and PIs in comparison to the total population and two major subtypes (CRF01 AE and B) Mutation RT HIV Total (721) numbers (%) Subtype B (n = 53) numbers (%) CRF01 AE (n = 640) numbers (%) p-Value NRTIs M41L 195(27%) 7(13%) 182(28%) 0.016a E44D 62(9%) 3(6%) 54(8%) 0.61 A62V 22(3%) 4(8%) 17(3%) 0.069 K65R 34(5%) 6(11%) 26(4%) 0.029a D67N 299(42%) 18(34%) 271(42%) 0.25 T69D 36(5%) 3(6%) 30(5%) 0.733 INS69 3(1%) 0(0%) 1(0.2%) 1 K70R 187(26%) 10(19%) 170(27%) 0.256 L74V 38(5%) 5(9%) 32(5%) 0.192 V75I 23(3%) 3(6%) 18(3%) 0.212 F77L 14(2%) 3(6%) 9(1%) 0.057 Y115F 11(2%) 5(9%) 6(1%) 0.001a F116Y 26(4%) 3(6%) 21(3%) 0.419 V118I 138(19%) 8(15%) 124(19%) 0.585 Q151M 36(5%) 4(8%) 30(5%) 0.32 M184V/I 297(41%) 22(42%) 269(42%) 1 L210W 150(21%) 7(13%) 134(21%) 0.215 T215F/Y 283(39%) 15(28%) 257(40%) 0.107 K219Q/E 184(26%) 12(23%) 168(26%) 0.628 NNRTIs L1001 17(2%) 2(4%) 16(3%) 0.641 K103N 161(22%) 10(19%) 145(23%) 0.609 V106A/M 20(3%) 2(4%) 15(2%) 0.378 V108I 61(8%) 5(9%) 54(8%) 0.797 Y181C/I 121(17%) 9(17%) 108(17%) 1 Y188C/L/H 41(6%) 2(4%) 39(6%) 0.761 G190A/S 128(18%) 7(13%) 118(18%) 0.457 P225H 27(4%) 0(0%) 26(4%) 0.251 M230L 10(1%) 1(2%) 9(1%) 0.551 Protease L10F/I/R/V 6(1%) 2(4%) 2(0.3%) 0.031 K20M/R/I/T 3(1%) 1(2%) 0(0%) 0.076 L33F/I/V 4(1%) 2(4%) 1(0.2%) 0.016a M36I/L/V 88(12%) 2(4%) 94(15%) 0.022a M46I/L 39(5%) 0(0%) 32(5%) 0.163 I47V/A 1(1%) 0(0%) 1(0.2%) 1 G48V 17(2%) 2(4%) 13(2%) 0.32 F53L 11(2%) 0(0%) 11(2%) 1 I54VL/M/T/S 37(5%) 4(8%) 30(5%) 0.32 L63P 183(25%) 33(62%) 140(22%) 0a A71V/T 34(5%) 12(23%) 17(3%) 0a G73A/C/S/T 4(1%) 2(4%) 1(0.2%) 0.016a V82A/T/F/S 37(5%) 3(6%) 33(5%) 0.531 I84V 8(1%) 1(2%) 6(1%) 0.428 N88D/S 12(2%) 3(6%) 7(1%) 0.035a L90M 35(5%) 8(15%) 26(4%) 0.003a a Marker indicates the statistically significant difference between subtypes calculated by Fisher`s exact test.
X
ABCC8 p.Val118Ile 18462814:72:844
status: NEW